The global single cell analysis market size was estimated at 2.29 billion in 2019 and is projected to expand at a CAGR of 16.9% during the forecast period. Recent developments in the OMICs method with respect to technology, specificity, scale, and timelines, have enabled a comprehensive analysis of transcriptome and genome at an individual cellular level. Moreover, technological advancements in Single cell manipulation and amplification techniques have led to the implementation of high throughput technologies in assays, in turn driving the revenue growth.
Ongoing technological advancements, such as the advent of Single cell RNA sequencing, have opened new research avenues for the detection of molecular changes which aids in disease etiology for specific cell types. This application enhances the identification of highly specific and diagnostic biomarkers, as well as therapeutic targets, consequently increasing adoption within both the diagnostic and pharmaceutical industries.
Introduction of massively parallel analysis tools such as BD’s Rhapsody single cell analysis system enables assessment of a substantial number of genes across tens of thousands of single cells in parallel. BD has also demonstrated the efficiency of its product in the identification of rare cell populations including a rare T-cell subset and stem memory T-cells. Furthermore, the development of advanced therapies for cancer treatment is expected to impact the market significantly. Companies have incorporated these assays into their CAR platform to derive more precise information for the development of CAR-T therapy.
The market for single cell analysis is still at an infant stage as compared to other associated markets such as genomics and sequencing market. However, several commercial players such as Illumina and Bio-Rad are investing in the development of solutions. This factor can be considered as a lucrative opportunity for revenue generation in the forthcoming years.
Frequent purchase and high usability of products offered under the consumables segment resulted in the highest revenue generation in this segment. Out of all the consumables, reagents accounted for the major revenue share with 55.8% share of the single cell analysis market in 2019. The high usage of the product across multiple applications, such as probing, identification, sorting, and immuno-phenotyping can be attributed to the growth of the segment.
Moreover, factors such as the purity and availability of suitable reagents have a direct impact on the efficiency and efficacy of the assay techniques. Thus, investment in reagent development to cater to the various research needs during analysis at the individual cellular level has driven the market. Microscope, hemocytometers, flow cytometers, NGS systems, and PCR are the key revenue-generating instruments and accounted for over 60% market share in terms of revenue, in 2019.
A decline in sequencing price along with constant introduction of new products to simplify the sample preparation step in sequencing is anticipated to accelerate the revenue share of this segment in the forthcoming years. Automated counters are anticipated to witness the fastest growth over the forecast period, owing to the shift in trend from manual workflows to automated assays in research institutes.
Currently, a substantial number of research entities have begun combining single cell genomics with single cell proteomics to investigate various therapeutic areas, such as cancer, neuroscience, and infectious disease at a Single cellular level. Implementation of single cell multi-omics methods in oncology has created diagnostics and therapeutic opportunities for cancer management.
Single cell analysis has effectively addressed the limitations of data resolution and has provided a detailed understanding of the tumor progression, metastasis, immune evasion, and treatment resistance. These factors have led to the huge adoption of this technology in cancer biology and thus resulted in the estimated dominance of this segment.
The application of this technology to the field of immunology has accelerated the investigation of developmental trajectories during immune responses. Moreover, it is anticipated that the immunological arena would witness a continued increase in adoption of multi-omics analysis techniques to acquire in depth information in this field, which in turn, is expected to bolster the product adoption.
Single cell analysis technology is increasingly being used in research settings. Experimental approaches that utilize the technology, have enabled the biologists to gain biological cellular networks related intricacies which further accelerate the development of new ways to diagnose and treat disease. As a result, a substantial number of research entities are utilizing this technology, thus contributing to the larger share of academic and research laboratories.
Although this market is at the infant stage in current space, it exhibits the potential to improve the accuracy and specificity of disease diagnosis based on knowledge of inter- and intra-cellular networks. Moreover, emerging trend for implementation of circulating tumor cells-based cancer diagnostics is anticipated to spur the revenue share of diagnostics in the forthcoming years.
This technology plays a vital role in the development of next-generation therapies, such as cancer immunotherapies, thereby driving revenue growth of biotechnology and pharmaceutical companies. For instance, companies like Creative Biolabs are engaged in designing next-generation sequencing and Single cell sequencing solutions to advance the development of CAR-T therapies.
Rapidly evolving omics market, including genomics, transcriptomics, epigenomics, and proteomics in the U.S. has led to the dominance of North America in 2019. Furthermore, the presence of major companies engaged in delivering high-throughput technologies, coupled with robust funding agencies in the U.S., has contributed to the large market share held by North America. Moreover, widening the scope of modern age therapeutics, such as IVF, and prenatal screening is augmenting the demand from the U.S.
Asia Pacific is projected to grow at the fastest CAGR during the forecast period. The expanding market operations of global companies, along with domestic ones, in Asian countries is indicative of growing Asia Pacific market. For instance, in July 2019, U.S.-based Mission Bio., signed distribution agreement with Novogene Corporation for the sale of Mission Bio Tapestri Platform. The platform is a Single cell targeted DNA solution, designed for precise identification of cancer mutation profiles. This collaboration was a result of expanding China’s Next-generation Sequencing (NGS) market.
The major market players include but are not limited to, Illumina, Inc.; Thermo Fisher Scientific, Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; Merck Millipore GmbH; Fluidigm, 10x Genomics, Inc.; BGI; and Novogene Corporation. Apart from establishing collaborations with other players, the key companies are entering in long-term contracts with customer laboratories to understand and serve their specific needs.
The companies engage in the introduction of novel solutions with a competitive advantage. For instance, in January 2019, Fluidigm Corporation launched REAP-seq (RNA expression and protein sequencing) as the first commercially available, automated solution for multi-omic single cell analysis. They also engage in obtaining licenses to use novel technologies, which in turn, would boost their revenue growth. For instance, New York Genome Center has procured a license for BioLegend’ CITE-seq technology, a single cell level RNA sequencing technology.
Base year for estimation
Actual estimates/Historical data
2016 - 2019
2020 - 2027
Revenue in USD Million & CAGR from 2020 to 2027
North America, Europe, Asia Pacific, Latin America& MEA
U.S., Canada, U.K., Germany, China, India, Brazil, Mexico, & South Africa
Revenue, company share, competitive landscape, growth factors, trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global single cell analysis market report on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Next Generation Sequencing
High-content Screening System
Automated Cell Counters
Application Outlook (Revenue, USD Million, 2016 - 2027)
Non-invasive prenatal diagnosis
End-use Outlook (Revenue, USD Million, 2016 - 2027)
Academic & Research Laboratories
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Laboratories
Regional Outlook (Revenue, USD Million, 2016 - 2027)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.